<Suppliers Price>

Patritumab deruxtecan

Names

[ CAS No. ]:
2227102-46-5

[ Name ]:
Patritumab deruxtecan

Biological Activity

[Description]:

Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1].

[Related Catalog]:

Research Areas >> Cancer

[In Vitro]

Patritumab deruxtecan 对表达 HER3 突变的乳腺癌细胞表现出活性，无论HER2是否过表达[1]。 Patritumab deruxtecan (0-100 nM) 以浓度依赖性方式结合所有 HER3 突变体和 HER3WT MDA-MB-231 细胞的表面，但不结合 HER3< sup>EV 细胞[1].

[References]

[1]. Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.